AstraZeneca PLC
AZN Real Time Price USDRecent trades of AZN by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in AZN holdings by institutional investors
Quarterly net insider trading by AZN's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$1,350,000 Oct 17, 2025 Issue: Pharmacy Health Issues Medicare/Medicaid Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$1,840,000 Jul 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Tariff (miscellaneous tariff bills)
-
$1,240,000 Apr 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark
-
$640,000 Jan 21, 2025 Issue: Health Issues Medicare/Medicaid Pharmacy Taxation/Internal Revenue Code Copyright/Patent/Trademark Insurance
-
$650,000 Oct 21, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$950,000 Jul 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$700,000 Apr 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$80,000 Feb 07, 2024 Issue: Health Issues Medicare/Medicaid Pharmacy Budget/Appropriations
-
$830,000 Jan 22, 2024 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
-
$950,000 Oct 20, 2023 Issue: Copyright/Patent/Trademark Taxation/Internal Revenue Code Pharmacy Medicare/Medicaid Health Issues
AZN Estimated quarterly lobbying spending
AZN Revenue by Segment or Geography
New AZN patent grants
-
Patent Title: Pill dispenser Jul. 30, 2024
-
Patent Title: 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents Sep. 18, 2018
-
Patent Title: Anti-ifnar1 antibodies with reduced fc ligand affinity Jun. 05, 2018
-
Patent Title: Compound May. 22, 2018
-
Patent Title: [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases Apr. 17, 2018
-
Patent Title: 1,3,4-thiadiazole compounds and their use in treating cancer Apr. 10, 2018
-
Patent Title: Compounds and their use as bace inhibitors Mar. 20, 2018
-
Patent Title: Chemical compounds Feb. 27, 2018
-
Patent Title: Maleate salts of a quinazoline derivative useful as an antiangiogenic agent Feb. 13, 2018
-
Patent Title: Processes for the preparation of azd5363 and intermediate used therein Jan. 30, 2018
-
Patent Title: Chemical compounds Jan. 23, 2018
-
Patent Title: Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer Jan. 02, 2018
-
Patent Title: Chemical compounds Dec. 19, 2017
-
Patent Title: Mcl-1 inhibitors and methods of use thereof Dec. 12, 2017
-
Patent Title: Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer Nov. 21, 2017
-
Patent Title: Nmda antagonist prodrugs Nov. 21, 2017
-
Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Nov. 14, 2017
-
Patent Title: Combination treatment Sep. 19, 2017
-
Patent Title: Combination comprising an omega-3 fatty acid composition and an sglt2 inhibitor Sep. 12, 2017
-
Patent Title: Phenyl and benzodioxinyl substituted indazoles derivatives Aug. 22, 2017
-
Patent Title: Combination treatment of cancer Aug. 22, 2017
-
Patent Title: 2-(2,4,5-substituted-anilino)pyrimidine compounds Aug. 15, 2017
-
Patent Title: Quinazoline inhibitors of activating mutant forms of epidermal growth factor receptor Aug. 01, 2017
-
Patent Title: Chromenone derivatives Aug. 01, 2017
-
Patent Title: Compounds and methods for inhibiting jak Jul. 25, 2017
-
Patent Title: Combination of hmg-coa reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases Jul. 25, 2017
-
Patent Title: Methods of treating cancer with a pyrazole derivative Jun. 27, 2017
-
Patent Title: Chemical compounds May. 23, 2017
-
Patent Title: Compounds and uses May. 23, 2017
-
Patent Title: Mono-fluoro beta-secretase inhibitors May. 16, 2017
-
Patent Title: 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase Apr. 11, 2017
-
Patent Title: Chemical compounds Apr. 11, 2017
-
Patent Title: Bilayer tablet formulations Apr. 11, 2017
-
Patent Title: Pyrrolo[3,2-d]pyrimidin-4-one derivatives and their use in therapy Feb. 28, 2017
-
Patent Title: Methods of treatment using n-(3-fluorophenyl)-2-{3-[(7-{3-[ethyl(2-hydroxyethyl)amino]propoxy}-quinazolin-4-yl)amino]-1h-pyrazol-5-yl}acetamide Feb. 14, 2017
-
Patent Title: Maleate salts of a quinazoline derivative useful as an antiangiogenic agent Jan. 31, 2017
-
Patent Title: Certain (2 Dec. 20, 2016
-
Patent Title: Phenyl and benzodioxinyl substituted indazoles derivatives Dec. 06, 2016
-
Patent Title: Protein kinase b inhibitors Nov. 15, 2016
-
Patent Title: Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide Nov. 08, 2016
-
Patent Title: Nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) Oct. 25, 2016
-
Patent Title: Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient Oct. 18, 2016
-
Patent Title: Crystal structures of sglt2 inhibitors and processes for preparing same Sep. 27, 2016
-
Patent Title: Arginase inhibitors and methods of use thereof Sep. 20, 2016
-
Patent Title: Methods for improving asthma symptoms using benralizumab Sep. 13, 2016
-
Patent Title: Methods for increasing forced expiratory volume in asthmatics using benralizumab Sep. 13, 2016
-
Patent Title: Inhaler Nov. 04, 2014
-
Patent Title: Dental implant Mar. 11, 2014
-
Patent Title: Tablet Jul. 02, 2013
-
Patent Title: Tablet Apr. 12, 2011
Federal grants, loans, and purchases
- $1,810 2024-12-30 00:00:00 Agency: Department of Health and Human Services
- $2,076 2024-12-30 00:00:00 Agency: Department of Health and Human Services
- $0 2024-04-24 00:00:00 Agency: Department of Veterans Affairs
- $2,023 2024-01-02 00:00:00 Agency: Department of Health and Human Services
- $1,764 2024-01-02 00:00:00 Agency: Department of Health and Human Services
- $20,322 2023-07-27 00:00:00 Agency: Department of Health and Human Services
Estimated quarterly amount awarded to AZN from public contracts
Recent insights relating to AZN
Recent picks made for AZN stock on CNBC
ETFs with the largest estimated holdings in AZN
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $AZN stock a Buy, Sell, or Hold?
- What is the price target for $AZN stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $AZN stock?
- Who owns the most shares of $AZN stock?
- What funds own $AZN stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view AZN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.